Navigation Links
Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Date:5/18/2009

Ellman International launches next-generation aesthetic skin tightening technology

OCEANSIDE, N.Y., May 18 /PRNewswire/ -- Ellman International, Inc. announced today that the Food and Drug Administration (FDA) has granted clearance to Pelleve(TM), a skin tightening system for the non-ablative treatment of mild to moderate facial wrinkles and rhytids for skin phototypes I-IV. The clearance was granted based on clinical data demonstrating that a single treatment with the high frequency radiowave device can safely and effectively tighten and improve the appearance of skin on the face through six months.

"Today's FDA clearance of the Pelleve system represents a very exciting step in the introduction of next-generation high frequency radiowave technology to physicians and patients in the United States," said Rick Epstein, CEO of Ellman International, Inc. "Pelleve offers safe, non-invasive facial rejuvenation with no need for a local anesthetic and minimal discomfort -- a significant evolution from previous-generation technologies in this class."

Pelleve uses the advanced radiowave technology of the Ellman International Surgitron(R) Dual RF(TM) S5 and a proprietary Pelleve handpiece to precisely deliver energy through the skin to the dermal tissue beneath without damaging the epidermis. This gentle heating of the deeper dermal tissue induces collagen denaturization and contraction. As the dermal tissue recovers, new collagen synthesis occurs, which creates a tightening effect. The result is a noticeable improvement in skin quality and appearance with minimal side effects and healing time for patients.

In a clinical trial conducted to determine the effectiveness of the Pelleve system, 83 women and 10 men were given a single treatment with the Pelleve handpiece. The procedure was performed in an ambulatory (outpatient) setting with no need for skin cooling products or anesthesia and took an average of 15 to 20 minutes, depending on size of the area. More than 87% of patients showed measurable and immediate positive results in a blinded assessment of skin laxity and wrinkle improvement with continued response at six months after treatment. Patients were typically able to return to work and social activities immediately after treatment. Of the study population, two patients experienced small abrasions that healed within three days.

"Our research clearly demonstrates the power of the Pelleve Skin Tightening System. With a single Pelleve treatment, over 87% of our patients experienced an improvement in skin laxity and fewer overall facial wrinkles at six months. The Pelleve Skin Tightening System is an effective, non-invasive, economical and safe tool," said Dr. Antonio Rusciani, Division of Dermatology, Plastic and Reconstructive Surgery at the University of Rome in Rome, Italy.

Ellman's skin tightening technology has been marketed with a CE Mark in many countries since 2005 under the name Radiage. "We have seen positive results in many patients outside of the United States. Because this unique technology does not require anesthesia or cooling of the skin during the procedure, the physician can safely achieve the look of lifted, tighter skin without surgery, resulting in a more youthful appearance for the patient," said Dr. Kai Rezai, a noted dermatologist and Radiage user from Munster, Germany.

Designed to work in conjunction with the Surgitron Dual RF S5 platform, Ellman's patented 4.0 MHz radiowave unit, Pelleve handpieces represent just one of hundreds of accessories available for office and clinic environments. The Surgitron Dual RF S5 provides maximum control in precision cutting and energy delivery, with more versatility than other energy-based technologies. "Ellman's proven product platform enables medical professionals to perform surgical procedures that produce less tissue damage and pain than the competition. Adding Pelleve offers tremendous value to physicians, as customers ask for the latest in cosmetic correction from their dermatologists, plastic surgeons and other healthcare professionals," said Epstein. Pelleve will be introduced to the U.S. market this month through dermatologists, plastic surgeons, ENTs and other cosmetic surgery clinics.

For more information about Pelleve and the Surgitron Dual RF S5 system or to locate doctors using this unique high radiofrequency technology, visit www.pelleve.com or call 1-800-835-5535.

About Ellman International

Established in 1959, Ellman International (Oceanside, New York) is a privately held manufacturer of medical devices used to perform a variety of surgical procedures principally requiring cutting, coagulating, tissue ablation and vaporization. The company's products are based on patented and proprietary technologies utilizing high frequency radiowaves to perform traditional scalpel, scissor, electrosurgery and laser procedures. For more information, please visit www.ellman.com.


'/>"/>
SOURCE Ellman International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
2. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
3. NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device
4. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
5. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
6. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
7. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
8. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
9. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
10. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
11. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):